Yanik |
ASCT0521 |
57 |
Phase 2 study of TNF blockade
with etanercept for the treatment of idiopathic pneumonia syndrome
(IPS). 28 IPS patients were treated and a high rate of complete
responses, 71%. |
Etanercept is standard of care for pediatric
IPS |
Pulsipher |
ASCT 0431 – Ancillary analysis |
7 |
IgH-V(D)J NGS-MRD predicted relapse and survival post-HCT better than
flow MRD. Relapse 0 vs 16%, 2 yr OS 96% vs 77% |
PTCTC ONC1701
(EndRAD Trial) to test radiation free conditioning in NGS MRD-
patients |
Wagner |
BMT CTN 0501 |
17 |
Survival similar for both
single vs double cord blood transplants (73% vs 65%) but better
platelet recovery and less grade 3-4 GVHD with single cord |
Single cord
blood unit HCT preferred for children |
Dvorak |
ASCT1221 |
13 |
Tested BuCyMel vs BuFlu
regimens in JMML patients. More complications with BuCyMel but more
relapses with BuFlu. |
BuCyMel remains standard of care despite more
complications |